Alector and GSK partnership to end after dementia, Alzheimer’s drug failures

GSK ends brain drug alliance with Alector

Clinical setbacks derailed what was once a potentially $2.2 billion deal that marked GSK's return to neuroscience.

Alector stock plummets 13% as GSK terminates neuroscience pact (GSK:NYSE)

GSK ends Alector neuroscience deal after antibody trial failures in Alzheimer’s and FTD, sending ALEC shares down.

GSK ends Alector alliance as both lead assets fail

GSK has ended its five-year neuroscience partnership with Alector after latozinemab and nivisnebart both failed to deliver on their potential.

GSK walks away from Alector pact as immuno-neurology bet fizzles

After two high-profile trial failures over the past year, GSK is breaking off a deal that features $700 million upfront that it signed with Alector for neurodegenerative disease treatments. GSK’s exit effectively ...

Roy Jakobs to join GSK board

GSK plc has announced that Roy Jakobs will join the board of the company as a non-executive director from 13 July 2026. Jakobs is currently chief executive officer of Royal Philips, a global leader in health technology headquartered in Amsterdam, Netherlands. He has served as CEO of Royal Philips since 2022, having joined the company in 2010. Jakobs has also held senior roles at other global companies including Shell and Elsevier, and brings int…